COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review
Abstract Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the
severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients …
severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients …
Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research
B Bikdeli, MV Madhavan, A Gupta… - Thrombosis and …, 2020 - thieme-connect.com
Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness
caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The …
caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The …
Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized …
2 METHODS This guidance statement is a collaborative effort of the Perioperative and
Critical Care Thrombosis and Haemostasis Subcommittee, along with members of the …
Critical Care Thrombosis and Haemostasis Subcommittee, along with members of the …
Modified IMPROVE VTE risk score and elevated D-dimer identify a high venous thromboembolism risk in acutely ill medical population for extended …
AC Spyropoulos, C Lipardi, J Xu, C Peluso, TE Spiro… - TH …, 2020 - thieme-connect.com
An individualized approach to identify acutely ill medical patients at increased risk of venous
thromboembolism (VTE) and a low risk of bleeding to optimize the benefit and risk of …
thromboembolism (VTE) and a low risk of bleeding to optimize the benefit and risk of …
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum
GD Barnes, A Burnett, A Allen, J Ansell… - Journal of thrombosis …, 2022 - Springer
Thromboembolism is a common and deadly consequence of COVID-19 infection for
hospitalized patients. Based on clinical evidence pre-dating the COVID-19 pandemic and …
hospitalized patients. Based on clinical evidence pre-dating the COVID-19 pandemic and …
Coagulopathy, venous thromboembolism, and anticoagulation in patients with COVID‐19
PP Dobesh, TC Trujillo - Pharmacotherapy: The Journal of …, 2020 - Wiley Online Library
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has led to a worldwide
pandemic, and patients with the infection are referred to as having COVID‐19. Although …
pandemic, and patients with the infection are referred to as having COVID‐19. Although …
Post-discharge prophylaxis with rivaroxaban reduces fatal and major thromboembolic events in medically ill patients
Background Hospitalized acutely ill medical patients are at risk for fatal and major
thromboembolic events. Whether use of extended-duration primary thromboprophylaxis can …
thromboembolic events. Whether use of extended-duration primary thromboprophylaxis can …
Rivaroxaban for prevention of thrombotic events, hospitalization, and death in outpatients with COVID-19: a randomized clinical trial
G Piazza, AC Spyropoulos, J Hsia, M Goldin… - Circulation, 2023 - Am Heart Assoc
Background: COVID-19 (coronavirus disease 2019) is associated with heightened risks of
venous and arterial thrombosis and hospitalization due to respiratory failure. To assess …
venous and arterial thrombosis and hospitalization due to respiratory failure. To assess …
Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study
WH Capell, ES Barnathan, G Piazza… - American heart …, 2021 - Elsevier
Background COVID-19 is associated with both venous and arterial thrombotic complications.
While prophylactic anticoagulation is now widely recommended for hospitalized patients …
While prophylactic anticoagulation is now widely recommended for hospitalized patients …
Efficacy and safety considerations with dose-reduced direct oral anticoagulants: a review
Importance Dose-reduced regimens of direct oral anticoagulants (DOACs) may be used for
2 main purposes: dose-adjusted treatment intended as full-intensity anticoagulation (eg, for …
2 main purposes: dose-adjusted treatment intended as full-intensity anticoagulation (eg, for …